MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Intraperitoneal Chemotherapy

Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma.

Annals of Surgical Oncology 2019 May 8 [Link] Ali YM, Sweeney J, Shen P, Votanopoulos K, McQuellon R, Duckworth K, Perry KC, Russell G, Levine EA Abstract INTRODUCTION: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is an accepted treatment for peritoneal mesothelioma. In this study, we evaluated QOL after HIPEC for peritoneal mesothelioma. METHODS: This […]

Comments Off on Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma.

50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.

Annals of Surgical Oncology 2019 May 7 [Link] Letica-Kriegel AS, Leinwand JC, Sonett JR, Gorenstein LA, Taub RN, Chabot JA, Kluger MD Abstract BACKGROUND: The most common sites of malignant mesothelioma are the pleura and peritoneum, but little is known about the incidence, prognosis, or treatment of patients with disease in both cavities. Previous series […]

Comments Off on 50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.

The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma.

European Journal of Surgical Oncology 2019 March 23 [Link] Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S Abstract Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and […]

Comments Off on The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma.

Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.

Casopis Lekaru Ceskych 2019 Winter [Link] Klos D, Riško J, Stašek M, Loveček M, Hanuliak J, Skalický P, Lemstrová R, Mohelníková BD, Študentová H, Neoral Č, Melichar B. The tumors of the peritoneal surface, both primary and secondary, are associated with a very poor prognosis and rapid progression through conventional oncology treatment including systemic chemotherapy, […]

Comments Off on Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.

Malignant Peritoneal Mesothelioma: Treatment Options and Survival.

Anticancer Research 2019 February [Link] Salo SAS, Ilonen I, Laaksonen S, Myllärniemi M, Salo JA, Rantanen T Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPeM) is a rare type of cancer with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival. Treatment and survival of patients with MPeM have […]

Comments Off on Malignant Peritoneal Mesothelioma: Treatment Options and Survival.

Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry.

Annals of Surgical Oncology 2019 January 11 [Link] Vogin G1, Hettal L, Vignaud JM, Dartigues P, Goere D, Ferron G, Heyd B, Bereder JM, Tuech JJ, Glehen O,  de Chaisemartin C, Lherm Y, Villeneuve L, Kepenekian V, Marchal F BACKGROUND: Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare entity. Questions regarding management are still being debated as no more than 50 cases have been reported in the literature. OBJECTIVE: […]

Comments Off on Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry.

Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry.

European Journal of Surgical Oncology 2018 October 19 [Link] Deraco M, Nizri E, Glehen O, Baratti D, Tuech JJ, Bereder JM, Kepenekian V, Kusamura S, Goere D Abstract BACKGROUND: Well differentiated papillary peritoneal mesothelioma (WDPPM) is a rare variant of mesothelioma which affects mainly women in the reproductive age. The disease may present multifocally and […]

Comments Off on Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry.

Update on the management of malignant peritoneal mesothelioma.

Translational Lung Cancer Research 2018 October [Link] Sugarbaker PH Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease whose natural history is confined to the peritoneal space. Systemic chemotherapy has little impact on survival of patients with MPM. A surgical procedure with a goal of resection of all visible evidence of disease, called cytoreductive surgery […]

Comments Off on Update on the management of malignant peritoneal mesothelioma.

Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.

Annals of Gastroenterology 2018 Nov-Dec [Link] Boussios S, Moschetta M, Karathanasi A, Tsiouris AK, Kanellos FS, Tatsi K, Katsanos KH, Christodoulou DK Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease with a wide clinical spectrum. It arises from the peritoneal lining and commonly presents with diffuse, extensive spread throughout the abdomen and, more rarely, […]

Comments Off on Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.

First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications.

BMC Medical Genetics 2018 August 15 [Link] Löffler MW, Steinhilber J, Hilke FJ, Haen SP, Bösmüller H, Montes-Mojarro IA, Bonzheim I, Stäbler A, Faust U, Grasshoff U, Königsrainer I, Rammensee HG, Kanz L, Königsrainer A, Beckert S, Riess O, Schroeder C Abstract BACKGROUND: The PTEN-hamartoma-tumor-syndrome (PHTS) is caused by germline mutations in Phosphatase and Tensin […]

Comments Off on First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications.